ライフサイエンスコーパス: C. trachomatis

1 C. trachomatis and T. vaginalis infection increase the s

2 C. trachomatis assembles its membrane systems from the u

3 C. trachomatis has adjacent genes encoding the separate

4 C. trachomatis samples were typed using multilocus seque

5 C. trachomatis seropositivity was detected in 90% of the

6 C. trachomatis strains can be differentiated by sequenci

7 C. trachomatis was detected at follow-up in 39 subjects

8 C. trachomatis was detected from 59 rectal swabs and 8 p

9 C. trachomatis was subjected to low-level ethyl methanes

10 C. trachomatis was the most commonly detected agent in f

11 se seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%).

12 homa (TF) was detected in 65 children (14%), C. trachomatis was detected in 25 (5%), and bacterial pa

13 The Versant CT/GC assay detected 15 C. trachomatis serovars and 46 GC strains.

14 e, 37/45 C. trachomatis-positive and 197/212 C. trachomatis-negative samples were detected (sensitivi

15 e, 34/45 C. trachomatis-positive and 197/212 C. trachomatis-negative samples were detected (sensitivi

16 The 25 C. trachomatis specimens with PCR-positive results (obta

17 hom 52 tested C. trachomatis positive and 41 C. trachomatis negative.

18 Using the 16S rRNA assay alone, 34/45 C. trachomatis-positive and 197/212 C. trachomatis-negat

19 Using the plasmid-based assay alone, 37/45 C. trachomatis-positive and 197/212 C. trachomatis-negat

20 reated HLA-DR4 transgenic mice with 5 x 10(5)C. trachomatis D inclusion forming units (IFU) induced a

21 matis ocular serovars) were reacted with 908 C. trachomatis proteins, 447 antigens were recognized by

22 e genetics to evaluate the contribution of a C. trachomatis gene to disease pathogenesis.

23 Replacing C. muridarum pgp5 with a C. trachomatis pgp5 still inhibited the plasmid-dependen

24 Additionally, C. trachomatis replication depends on a subset of altere

25 ection frequently occurs within months after C. trachomatis infection treatment.

26 ficantly higher titers of antibodies against C. trachomatis ocular serovars A and B than ocular serov

27 or CD4(+) T cell-mediated protection against C. trachomatis infection in the genital mucosa.

28 idate CtFabI as a therapeutic target against C. trachomatis.

29 en candidate for a potential vaccine against C. trachomatis.

30 Furthermore, L-1MT addition allowed C. trachomatis to undergo secondary differentiation, alb

31 5% confidence interval [CI], 9.5%-24.0%) and C. trachomatis prevalence was 14.7% (95% CI, 7.8%-21.6%)

32 (odds ratio [OR] 0.85, 95% CI 0.75-0.95) and C. trachomatis infection (OR 0.67, 95% CI 0.55-0.78).

33 tion testing would detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is n

34 ssed transcription from the E. coli nrdH and C. trachomatis nrdAB promoters in vivo.

35 d urine detection rates for T. vaginalis and C. trachomatis within this age demographic demonstrated

36 ia species associated with human disease are C. trachomatis, which is the leading cause of both repor

37 DNA for whole-genome sequencing; however, as C. trachomatis is an obligate intracellular pathogen, th

38 often infected with heterosexual-associated C. trachomatis strains.

39 mido thiazolino 2-pyridones which attenuated C. trachomatis infectivity without affecting host cell o

40 d in the C-terminal half of the protein, but C. trachomatis serovar L2 has only one characterized dom

41 tes of the proportion of PID cases caused by C. trachomatis are 35% (95% credible interval [CrI], 11%

42 D, but the proportion of PID cases caused by C. trachomatis is unclear.

43 um is probably longer than for NGU caused by C. trachomatis.

44 ng subversion of cellular innate immunity by C. trachomatis.

45 he NOD2-dependent activation of NF-kappaB by C. trachomatis-infected cell lysates as a biomarker for

46 hospholipid molecular species synthesized by C. trachomatis contained oleic acid, an abundant host fa

47 included 98 women who were contact-traced by C. trachomatis-positive sex partners at the STI outpatie

48 Upon entry into host cells, C. trachomatis resides within a membrane-bound compartme

49 by comparison to a 6-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of th

50 provides another target for agents to combat C. trachomatis infection.

51 mpt to elucidate the mechanism that controls C. trachomatis adaptability.

52 For decades C. trachomatis has been considered an "energy parasite"

53 o exert their effector function and decrease C. trachomatis burden.

54 ption-mediated amplification (TMA) to detect C. trachomatis and N. gonorrhoeae and to determine if TM

55 Cepheid Xpert CT/NG assay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharynge

56 than that of SOC testing (96%) for detecting C. trachomatis (P = 0.167).

57 eatment were new infections with a different C. trachomatis strain rather than reinfection with the s

58 trains, no evidence was found that different C. trachomatis strains circulated in distinct subpopulat

59 We show that direct C. trachomatis infection of the murine upper genital tra

60 orted more often in subjects with discordant C. trachomatis strains than in those with concordant str

61 Half of the subjects with discordant C. trachomatis strains who reported sexual activity sinc

62 277 samples from 260 MSM identified distinct C. trachomatis strains circulating concurrently over tim

63 This study investigates whether distinct C. trachomatis strains circulate among subpopulations wi

64 -/-), and IL-4Ralpha(-/-) mice with low-dose C. trachomatis inoculums.

65 days, respectively) in two studies: (i) dry C. trachomatis-seeded swabs were used with ACT after sto

66 fic cysteine proteases, the caspases, during C. trachomatis genital infection causes the disruption o

67 tected in the cytoplasm of host cells during C. trachomatis infection and was highly enriched in the

68 poor memory CD8(+) T cell development during C. trachomatis infection of mice.

69 recognized by human antisera produced during C. trachomatis infection but not by animal antisera rais

70 g different urine samples spiked with either C. trachomatis or N. gonorrhoeae, and also containing bo

71 , reported recent sexual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an

72 ores the CD8(+) T cell response and enhances C. trachomatis clearance.

73 the fecal-oral route; (2) in the modern era, C. trachomatis causes "opportunistic" infection at non-G

74 quantitative real-time PCR gene expression, C. trachomatis detection, and nonchlamydial bacterial cu

75 Finally, C. trachomatis infection interferes with the SNX5:CI-MPR

76 For C. trachomatis, neither system was >95% sensitive from t

77 For C. trachomatis, Xpert was 95% sensitive (95% CI, 86 to 9

78 [95% confidence interval {CI}, .20-1.23] for C. trachomatis infection, 0.56 [95% CI, .19-1.67] for N.

79 d N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and highest i

80 Coinfection prevalences were 1.3% for C. trachomatis/T. vaginalis, 0.61% for C. trachomatis/N.

81 ed with 2.1% for N. gonorrhoeae and 1.6% for C. trachomatis.

82 % for C. trachomatis/T. vaginalis, 0.61% for C. trachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vagi

83 ween the two conditions tested were >98% for C. trachomatis and 100% for N. gonorrhoeae.

84 izing it to kynurenine with consequences for C. trachomatis, which is a tryptophan auxotroph.

85 fferent chemokine receptors are critical for C. trachomatis-specific CD4(+) T cells to home to the lu

86 nstrate that FASII activity is essential for C. trachomatis proliferation within its eukaryotic host

87 The enrollment visit OmpA genotypes for C. trachomatis were determined for 162 subjects (92% fem

88 n used to predict up to 59 putative Incs for C. trachomatis; however, localization to the inclusion m

89 ion of 300 colony forming units (CFU)/mL for C. trachomatis and 1500CFU/mL for N. gonorrhoeae.

90 s that no separate transmission networks for C. trachomatis among MSM existed.

91 ddition to the available testing options for C. trachomatis and N. gonorrhoeae.

92 p in 9 of 11 (82%) participants positive for C. trachomatis and 7 of 10 (70%) participants positive f

93 le participants, 41 (8.2%) were positive for C. trachomatis, 21 (4.2%) were positive for N. gonorrhoe

94 lex cytoskeletal rearrangements required for C. trachomatis entry into host cells.

95 polymerase chain reaction [PCR] results for C. trachomatis DNA by Roche Amplicor) and 25 true-negati

96 age groups suggests that women screened for C. trachomatis/N. gonorrhoeae, whether asymptomatic or s

97 tions in U.S. women undergoing screening for C. trachomatis/N. gonorrhoeae.

98 two methods did not differ significantly for C. trachomatis (P = 0.774) or N. gonorrhoeae (P = 0.163)

99 esulted in collection of 2,408 specimens for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA scr

100 f a true "gold standard" diagnostic test for C. trachomatis.

101 and transport medium (n = 5) were tested for C. trachomatis rRNA by NAAT.

102 Subjects were enrolled, tested for C. trachomatis, treated with azithromycin, and scheduled

103 predictive values of 3 diagnostic tests for C. trachomatis infection.

104 e the development of specific treatments for C. trachomatis.

105 Plasmid-free C. trachomatis is also attenuated in both the mouse geni

106 Plasmid-free C. trachomatis serovar L2 organisms can be transformed w

107 econd HLA-B27-restricted T-cell epitope from C. trachomatis with relevance in ReA demonstrated to be

108 mydial species, we cloned hctA and ihtA from C. trachomatis serovar D, C. muridarum, C. caviae and C.

109 ia pseudotuberculosis and also secreted from C. trachomatis in infected cells where it localizes appr

110 ating the potential role of gastrointestinal C. trachomatis in human chlamydial pathogenesis.

111 Genital C. trachomatis strains can counter tryptophan limitation

112 s-mucosa protective immunity against genital C. trachomatis infection following intranasal immunizati

113 ositive predictive values for M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 10

114 n >/= 40 years old (>11%), while the highest C. trachomatis prevalence (9.2%) and N. gonorrhoeae prev

115 transgenic mouse model for evaluating human C. trachomatis vaccine antigens are discussed.

116 ice, which replicates many features of human C. trachomatis infection and avoids the characteristic l

117 The current study, by mapping immunodominant C. trachomatis antigens and identifying antigens associa

118 nished protective role for CD4(+) T cells in C. trachomatis murine infection might lead to new insigh

119 evelopmentally controlled ompA expression in C. trachomatis.

120 Furthermore, in C. trachomatis, glgA and other plasmid-responsive chromo

121 s the complete deletion of specific genes in C. trachomatis L2.

122 the retained OmcBn was highly immunogenic in C. trachomatis-infected women, which is consistent with

123 cells to identify host factors important in C. trachomatis L2 infection.

124 expressing a FLAG-tagged version of IncD in C. trachomatis.

125 o NrdR boxes upstream of the nrdAB operon in C. trachomatis.

126 e data point to an AasC-dependent pathway in C. trachomatis that selectively scavenges host saturated

127 domain from a membrane-anchored permease in C. trachomatis could represent a previously uncharacteri

128 vidence of circulating genomic resistance in C. trachomatis.

129 xclusively labeled intrainclusion signals in C. trachomatis-infected cells permeabilized with saponin

130 , a major suppressor of metabolite supply in C. trachomatis-infected cells.

131 ator of sigma(66)-dependent transcription in C. trachomatis.

132 evelopments in the genetic transformation in C. trachomatis, we constructed a versatile green fluores

133 encodes a putative metal ion transporter in C. trachomatis.

134 C. trachomatis detection after treatment in C. trachomatis-infected subjects seen at a sexually tran

135 ne-bound intracellular niche, the inclusion, C. trachomatis relies on a set of effector proteins that

136 se signaling, were associated with increased C. trachomatis infection.

137 Therefore, probenecid may inhibit C. trachomatis growth by an as yet unresolved mechanism.

138 we bypass the cervix and directly inoculate C. trachomatis into the uterus.

139 tty acids were incorporated exclusively into C. trachomatis-produced phospholipid molecular species.

140 s added to the medium were incorporated into C. trachomatis-derived phospholipid molecular species.

141 uridarum, a model pathogen for investigating C. trachomatis pathogenesis, readily spreads from the mo

142 The exploitation of genetically labeled C. trachomatis organisms with P3-driven GFP allows for t

143 ifested itself in ocular, urogenital and LGV C. trachomatis strains, including the epidemic LGV serot

144 basis of bioinformatic analysis of multiple C. trachomatis genomes, led us to re-evaluate the previo

145 hus, we screened a population of mutagenized C. trachomatis strains for mutants that failed to reacti

146 Plasmid copy number, C. trachomatis load and disease severity were assessed i

147 uantitative ddPCR assay in diagnosing ocular C. trachomatis infections by comparing the performances

148 search and clinical use in diagnosing ocular C. trachomatis infections.

149 report the whole-genome sequences of ocular C. trachomatis isolates obtained from young children wit

150 ounts of N. gonorrhoeae and small amounts of C. trachomatis organisms.

151 P3 region verifies that P3 is a new class of C. trachomatis sigma(66)-dependent promoter, which requi

152 Culture of C. trachomatis has, until now, been a prerequisite to ob

153 Ms support the full infectious life cycle of C. trachomatis in a manner that mimics the infection of

154 N in situ at the late developmental cycle of C. trachomatis.

155 l specimens resulted in greater detection of C. trachomatis (6.1% and 11.3% rates, respectively) than

156 AC2 is superior to SDA for the detection of C. trachomatis and N. gonorrhoeae from rectal swab sampl

157 ssay can be recommended for the detection of C. trachomatis and N. gonorrhoeae in swab and urine spec

158 ive values of GeneXpert for the detection of C. trachomatis and N. gonorrhoeae were 86%, 99.2%, 92.5%

159 ays for ultrafast and sensitive detection of C. trachomatis DNA from vaginal swabs.

160 The detection of C. trachomatis in ocular specimens by NAAT was verified

161 egradation in the AC2 assay for detection of C. trachomatis or N. gonorrhoeae was observed, although

162 Probe Aptima Combo 2 assay) for detection of C. trachomatis ribosomal RNA (rRNA) from direct ocular s

163 fection prevented the first cell division of C. trachomatis, although the cell morphology suggested d

164 ic review to investigate the epidemiology of C. trachomatis organism load in human genital chlamydia

165 ays a significant role in the eradication of C. trachomatis during the infection of macrophages.

166 oyl-acyl carrier protein reductase (FabI) of C. trachomatis to determine whether chlamydial FASII is

167 cting the NCR of the primary sigma factor of C. trachomatis, sigma(66).

168 progress has been hindered by the failure of C. trachomatis to induce clinically relevant pathology i

169 A common feature of C. trachomatis persistence models is that reticulate bod

170 study the development-dependent function of C. trachomatis promoters in an attempt to elucidate the

171 mbination is widespread within the genome of C. trachomatis, thus whole-genome sequencing is necessar

172 uter membrane protein A (OmpA) genotyping of C. trachomatis strains.

173 ld be protected by vaccination, 10(4) IFU of C. trachomatis D was delivered intranasally, and mice we

174 rvically 6 weeks later with 5 x 10(5) IFU of C. trachomatis D.

175 of the delay was a block in the induction of C. trachomatis persistence by IFN-gamma.

176 mid-free lymphogranuloma venereum isolate of C. trachomatis, serovar L2, with either the original shu

177 swabs frequently contain very low levels of C. trachomatis DNA and large amounts of contaminating mi

178 The infectious load of C. trachomatis before MDA was determined in 30 children

179 d as few as 10 inclusion-forming units/ml of C. trachomatis in less than 9 min, including DNA extract

180 genotype had significantly increased odds of C. trachomatis (OR, 3.7; 95% CI, 1.6-8.8; P = .002).

181 rs were also associated with reduced odds of C. trachomatis infection: lack of ocular discharge (OR 0

182 species IhtA rescued the lethal phenotype of C. trachomatis serovar L2 HctA expression.

183 The prevalence of C. trachomatis by NAATs was 17.5%.

184 contributing to the increased prevalence of C. trachomatis in the human GI tract.

185 ting, the estimated population prevalence of C. trachomatis ocular infection was approximately 17.5%.

186 the cell surface similar to the proteins of C. trachomatis and C. pneumoniae.

187 drial fragmentation prevented replication of C. trachomatis even in p53-deficient cells.

188 This study demonstrates the role of C. trachomatis and number of recent sexual partners in t

189 Biochemical analysis established the role of C. trachomatis-encoded acyltransferases in producing the

190 tion of Cdu1 led to increased sensitivity of C. trachomatis for IFNgamma and impaired infection in mi

191 ting infectivity across multiple serovars of C. trachomatis without host cell toxicity.

192 Due to the genetically intractable status of C. trachomatis at that time, this model of IncD-CERT int

193 nome sequencing of representative strains of C. trachomatis from both trachoma and lymphogranuloma ve

194 The 1.58A crystal structure of C. trachomatis hypothetical protein CT263 presented here

195 AFN-1252 treatment of C. trachomatis-infected HeLa cells at any point in the i

196 ous findings and to advance understanding of C. trachomatis genetic expression.

197 NAs (miRNAs) in maintaining the viability of C. trachomatis-infected primary human cells.

198 d avoids the characteristic low virulence of C. trachomatis in the mouse, we previously demonstrated

199 conducted whole-genome sequence analysis on C. trachomatis isolates collected from a previously desc

200 Current data on C. trachomatis phylogeny show that there is only a singl

201 OmpA genotyping was performed on C. trachomatis-positive urogenital specimens obtained fr

202 ts with monoinfections with M. genitalium or C. trachomatis compared to women with no detectable STIs

203 immunized with the rMOMP of C. muridarum or C. trachomatis D, E, or F had lost 4%, 6%, 8%, and 8% of

204 to be significantly associated with TF/TI or C. trachomatis infection, and the use of sanitation faci

205 ssed during infection by the human pathogens C. trachomatis serovars L2, D and L2b and C. pneumoniae.

206 Currently, a vaccine to prevent C. trachomatis infections is not available.

207 Primary C. trachomatis infection of mice also causes no genital

208 strated a critical role of CPAF in promoting C. trachomatis survival in the mouse lower genital tract

209 Professional phagocytes provide C. trachomatis only a limited ability to survive and are

210 Using pure C. trachomatis, the MAMEF assays detected as few as 10 i

211 ng of Inc function(s), we subjected putative C. trachomatis Incs to affinity purification-mass spectr

212 For the qualitative RealTime C. trachomatis/N. gonorrhoeae assay, the overall agreeme

213 f anal intercourse, were screened for rectal C. trachomatis using the Gen-Probe Aptima COMBO 2 Assay.

214 revalence and factors associated with rectal C. trachomatis among female sexually transmitted infecti

215 scheduled for a 6-month follow-up for repeat C. trachomatis testing.

216 Our study demonstrates that most repeat C. trachomatis detections after treatment were new infec

217 ng to investigate the epidemiology of repeat C. trachomatis detection after treatment in C. trachomat

218 tool in understanding the origins of repeat C. trachomatis detection after treatment.

219 er in those with versus those without repeat C. trachomatis detection.

220 In this review, we revisit C. trachomatis pathogenesis data from mice and humans us

221 ere we present the structure of the secreted C. trachomatis protein Pgp3, an immunodominant antigen a

222 Incidence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infecti

223 fection, a model that has been used to study C. trachomatis pathogenesis in women, is known to depend

224 nse, is unable to protect against subsequent C. trachomatis infections.

225 t within a few days, while a CPAF-sufficient C. trachomatis strain (L2-5) survived in the lower genit

226 Although several lines of evidence suggest C. trachomatis utilizes host phospholipids, the bacteriu

227 haracterized for 93 women, of whom 52 tested C. trachomatis positive and 41 C. trachomatis negative.

228 eless, C. muridarum Pgp5 is more potent than C. trachomatis Pgp5 in suppressing gene expression.

229 tions were significantly more prevalent than C. trachomatis and N. gonorrhoeae infections, while the

230 T. vaginalis was more prevalent than C. trachomatis or N. gonorrhoeae in all age groups excep

231 In this study, we demonstrate that C. trachomatis infection of the upper genital tract resu

232 We hypothesize that C. trachomatis also predisposes to EP by altering FT PRO

233 Our results indicate that C. trachomatis profoundly remodels the host proteome ind

234 Our results indicate that C. trachomatis utilizes functionally diverse genes to me

235 ogether with the intriguing observation that C. trachomatis CopN does not bind tubulin, our data supp

236 Genomic analysis predicts that C. trachomatis is capable of type II fatty acid synthesi

237 We now report that C. trachomatis Pgp3 can neutralize the antichlamydial ac

238 ry, this experimental approach revealed that C. trachomatis broadly alters host proteins and can be a

239 We show that C. trachomatis require mitochondrial ATP for normal deve

240 In this work, we are showing that C. trachomatis has an active respiratory metabolism that

241 The genomic data suggest that C. trachomatis respiratory chain could produce a sodium

242 The C. trachomatis FabI (CtFabI) is a homotetramer and exhib

243 The C. trachomatis homolog of TC0912 is encoded by a highly

244 The C. trachomatis polymorphic membrane protein D (PmpD) is

245 -negative TLR2 or IkappaBalpha abrogated the C. trachomatis-induced PROKR2 expression.

246 s TMA (12,999 specimens) on the basis of the C. trachomatis detection rate, specimen source distribut

247 We previously proposed that insertion of the C. trachomatis effector protein IncD into the inclusion

248 a presented here show that expression of the C. trachomatis effector protein IncD mediates the recrui

249 nstead being placed within UGT clades of the C. trachomatis phylogenetic tree.

250 The sensitivity and specificity of the C. trachomatis test were 100% and 99.8% for AC2 and 56.1

251 ars; P < 0.0001) and higher than that of the C. trachomatis-infected females (mean, 23.8 years; P = 0

252 The first assay targeted the C. trachomatis 16S rRNA gene, and the second assay targe

253 rRNA gene, and the second assay targeted the C. trachomatis cryptic plasmid.

254 For appropriate therapy, C. trachomatis conjunctivitis should be diagnosed defini

255 with relatively high titers of antibodies to C. trachomatis ocular serovars) were reacted with 908 C.

256 rtion of reproductive damage attributable to C. trachomatis Further studies using modern assays in co

257 amma) resistance of C. muridarum compared to C. trachomatis in the murine genital tract.

258 The PEFs of PID due to C. trachomatis decline steeply with age by a factor of a

259 lation excess fractions (PEFs) of PID due to C. trachomatis, using routine data, surveys, case-contro

260 tion of chlamydia might have been exposed to C. trachomatis but not infected.

261 elected by evolution as the host response to C. trachomatis in the human female genital tract to cont

262 terize the mucosal CD8(+) T cell response to C. trachomatis in the murine genital tract.

263 tigen specificities of antibody responses to C. trachomatis infection in individuals from trachoma-en

264 for successful CD4(+) T cell trafficking to C. trachomatis-infected tissues, we will be better equip

265 In both Chlamydia trachomatis (C. trachomatis) and C. pneumoniae, the PmpD protein is p

266 genital infection by Chlamydia trachomatis (C. trachomatis) is a major cause.

267 ice were more susceptible to a transcervical C. trachomatis D infection than WT mice.

268 eotide transporters, the ATP/ADP translocase C. trachomatis Npt1 (Npt1(Ct)) and the nucleotide unipor

269 nflammation- and caspase-inducing, wild-type C. trachomatis serovar L2 led to infertility, but the no

270 isolates appear to be recombinants with UGT C. trachomatis genome backbones, in which loci that enco

271 7,593 women (18 to 89 years old) undergoing C. trachomatis/N. gonorrhoeae screening using the Aptima

272 uridarum, a murine model of human urogenital C. trachomatis, with severely attenuated disease develop

273 igens that can be applied to humans, we used C. trachomatis serovar D (strain UW-3/Cx) to induce infe

274 Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalences were 8.7%

275 positive for T. vaginalis (P < 0.0002 versus C. trachomatis).

276 matis positive and the 212 samples that were C. trachomatis negative by NAATs, 33/45 and 197/212 were

277 Of the 45 samples that were C. trachomatis positive and the 212 samples that were C.

278 d vaginal squamous epithelial cells, whereas C. trachomatis did not.

279 infection (STI) in women of >40 years, while C. trachomatis and N. gonorrhoeae prevalence is lowest i

280 s5743618TT genotype was also associated with C. trachomatis (OR, 2.8; 95% CI, 1.3-6.2; P = .008).

281 olecules (TIRAP, MyD88) were associated with C. trachomatis among 205 African American women with cli

282 d that CVM was significantly associated with C. trachomatis infection (odds ratio [OR], 4.2 [95% conf

283 Host sphingomyelin was associated with C. trachomatis isolated by detergent extraction, but it

284 was to search for biomarkers associated with C. trachomatis-induced ocular pathologies.

285 Characteristics associating with C. trachomatis infection were examined using bivariable

286 to 18]) and there were no associations with C. trachomatis load or disease severity.

287 from patients with symptoms consistent with C. trachomatis conjunctivitis and with previously demons

288 By comparison, mice vaginally infected with C. trachomatis exhibited transient low-burden infections

289 ling of human epithelial cells infected with C. trachomatis plasmid-bearing (A2497) and plasmid-defic

290 l pathology also seen in women infected with C. trachomatis.

291 for tubal infertility in women infected with C. trachomatis.

292 mined for trachoma and ocular infection with C. trachomatis at baseline, and 6 months after mass drug

293 ical assays, we observed that infection with C. trachomatis led to downregulated expression of induci

294 or protection against genital infection with C. trachomatis.

295 Repeated infections with C. trachomatis lead to serious sequelae, such as inferti

296 n which the vaginal vault is inoculated with C. trachomatis do not recapitulate the course of human d

297 for up to 84 days and (ii) swabs seeded with C. trachomatis and N. gonorrhoeae and then placed in tra

298 Of the 35 subjects with C. trachomatis strains genotyped at enrollment and follo

299 gnificantly higher than those for women with C. trachomatis or N. gonorrhoeae (22.3 and 21.6, respect

300 red to obtain these electron carriers within C. trachomatis are poorly understood.